Asston Pharmaceuticals has announced robust financial results for the fiscal year ended March 31, 2026. The company reported a significant 23.32% increase in total revenue, reaching ₹3,158.43 lakhs, up from ₹2,561.02 lakhs in the previous year. Net profit for the fiscal year stood at ₹386.52 lakhs, reflecting the company’s strong performance and resilient business model. The annual report highlights continued progress towards strategic objectives and operational enhancements.
Asston Pharmaceuticals Reports Strong FY26 Financial Performance
Asston Pharmaceuticals Limited has announced its audited financial results for the fiscal year ended March 31, 2026, showcasing a substantial growth trajectory. The company reported a total revenue of ₹3,158.43 lakhs, marking an impressive increase of 23.33% compared to ₹2,561.02 lakhs in the preceding financial year.
Net Profit and Operational Resilience
The company’s net profit for FY 2025-26 was recorded at ₹386.52 lakhs. This achievement underscores the resilience of Asston Pharmaceuticals’ business model, its unwavering focus on operational efficiency, and sustained efforts to strengthen its market presence. The financial performance provides a solid foundation for the company’s strategic priorities and future expansion plans.
Strategic Progress and Future Outlook
The 7th Annual Report for FY 2025-26 details the company’s robust growth, continued progress towards strategic objectives, and significant enhancements in operational capabilities. Asston Pharmaceuticals remains committed to sustainable growth, profitability, and long-term value creation for its stakeholders, navigating the evolving global pharmaceutical landscape with agility and a focus on quality and regulatory compliance.
Key Financial Highlights
- Revenue from operations: ₹2,546.88 lakhs (FY 2025-26) vs. ₹2,503.92 lakhs (FY 2024-25)
- Other income: ₹611.55 lakhs (FY 2025-26) vs. ₹57.10 lakhs (FY 2024-25)
- Total income: ₹3,158.43 lakhs (FY 2025-26) vs. ₹2,561.02 lakhs (FY 2024-25)
- Profit before tax: ₹459.35 lakhs (FY 2025-26) vs. ₹501.60 lakhs (FY 2024-25)
- Profit after tax: ₹386.52 lakhs (FY 2025-26) vs. ₹385.28 lakhs (FY 2024-25)
- Earnings per equity share (Basic and Diluted): ₹4.92 (FY 2025-26) vs. ₹6.14 (FY 2024-25)
Source: BSE
